Search results
Fundamental Research Paved the Way for the Development of Vorasidenib
National Cancer Institute· 5 days agoDuring the 2023 American Society of Clinical Oncology (ASCO) annual meeting, a plenary presentation...
Mass. community organizes parade for 8-year-old cancer patient
WCVB Boston· 1 day agoAdelia, who is known as "Adelia the Wonder Girl" on social media, was diagnosed with diffuse midline...
New Sylvester Brain Tumor Institute offering personalized treatment
CBS News· 8 hours agoThere's a new way to treat patients with brain cancer at UM's Sylvester Comprehensive Cancer Center.
Candel Lights Up Investors' Portfolio With 830% Gain
RTT News· 3 hours agoShares of Candel Therapeutics Inc. (CADL) have gained more than 830% in the past 2 months, thanks to the substantial progress achieved across its clinical programs.
Researchers discover benefits of adding immune-boosting agent to personalized cancer vaccine
Medical Xpress· 7 days agoThe study, published in Nature Communications, found that pairing a personalized dendritic cell...
IRE1α determines ferroptosis sensitivity through regulation of glutathione synthesis - Nature...
Nature· 22 hours agoThe endoplasmic reticulum (ER) is a major site of lipid peroxidation during ferroptosis. Here authors show that the ER protein IRE1α determines ferroptosis induction via regulating glutathione synthesis independent of the unfolded protein response.
UC San Diego study finds plant virus may slow the progression of cancer
KSWB articles via Yahoo News· 1 day agoTo make the nanoparticles, researchers grew black-eyed pea plants and infected them with the virus....
Earnings call: Cyclacel Pharmaceuticals reports Q1 2024 results
Investing.com· 1 day agoCyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC ) has provided its first quarter financial results and...
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Proactive Investors· 6 days agoMazzo highlighted Lisata's effective cash management, with over $43 million in funds ensuring...
Chimerix (NASDAQ:CMRX) Upgraded by StockNews.com to “Hold”
ETF DAILY NEWS· 2 days agoStockNews.com upgraded shares of Chimerix (NASDAQ:CMRX – Free Report) from a sell rating to a hold rating in a report issued on Monday morning. CMRX has been the subject of several other research ...